Retatrutide vs tirzepatide: what can be compared
No trial has yet compared retatrutide with tirzepatide directly. What each drug's own trials show, and what the published ranking rests on.
Peptio Research
On this page8
No trial has randomised people to retatrutide and tirzepatide and reported a result. The one designed to do it, TRIUMPH-5, is a double-blind phase 3 trial in adults with obesity, and its registry record gives an estimated primary completion of November 2026 and no posted results 1. Until it reports, nobody knows which of the two lowers body weight more when the same kind of people take them under the same conditions. What can be compared now is how each molecule is built to act, where each stands with regulators, what each drug's own trials found against placebo, and what each has already been tested against directly.
Two molecules, one receptor apart
Tirzepatide acts on two receptors. Its US label describes it as "a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist" 2. Retatrutide acts on those two and a third: the paper reporting its first published phase 3 trial calls it "a GIP, GLP-1, and glucagon receptor agonist" 3, and the phase 2 obesity paper calls it a "Triple-Hormone-Receptor Agonist" 4.
Both come from Eli Lilly: retatrutide was developed under the code LY3437943 and tirzepatide under LY3298176, and the registry record of the trial that compares them names both codes 1.
So the structural difference that matters here is the glucagon receptor. None of the sources used for this page tests in people what that receptor adds, so nothing on this page attributes a clinical difference to it.
Where each stands with regulators
Tirzepatide is an approved medicine. FDA approved it as Mounjaro for type 2 diabetes on 13 May 2022 5 and as Zepbound for chronic weight management on 8 November 2023 6, and added obstructive sleep apnoea in adults with obesity to Zepbound's indications on 20 December 2024 7. In the EU it is authorised as Mounjaro, with a date of first authorisation of 15 September 2022 8. The tirzepatide page sets out each indication and the later approvals.
Retatrutide is not approved. FDA states that it is not a component of any FDA-approved drug and that the agency has made no finding of safety or efficacy for it for any condition 9. It has no entry in EMA's register of the medicines it has assessed, in the copy generated on 2 October 2026; that register covers medicines assessed centrally and does not cover authorisations by a single member state's agency 10. Lilly runs a pre-approval expanded access programme for retatrutide, first posted on 5 June 2026, for individual adults who cannot join a trial, and that is not an approval 11. The retatrutide page covers its status in more detail.
The two also differ on compounding. Tirzepatide injection was added to FDA's drug shortage list on 15 December 2022, and in an order dated 19 December 2024 FDA determined that the shortage was resolved 12. The grace periods that followed ended on 18 February 2025 for state-licensed pharmacies compounding under section 503A and on 19 March 2025 for outsourcing facilities under section 503B, and FDA's policy page, current as of 1 April 2026, says tirzepatide is on neither the drug shortage list nor the 503B bulks list 13. As of 31 May 2026, FDA had received more than 730 reports of adverse events associated with compounded tirzepatide, and it adds that it is not always possible to tell whether an event resulted from the drug 9. Retatrutide's position is simpler: FDA states that it "cannot be used in compounding under federal law" 9.
Both are also sold online under "research" labels. FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were "falsely labeled 'for research purposes' or 'not for human consumption.'" 9 Retatrutide is named in warning letters of March and August 2026 14 15, and tirzepatide in letters of February 2025, March 2026 and August 2026 16 14 15. In each, FDA found that evidence from the seller's website established that products labelled for research were drugs intended for human use 16 14 15. Every trial result on this page describes Lilly's product given under trial conditions. None of it describes a product sold that way.
What each drug's own trials found, against its own placebo
The tables below set the trials of each drug that are closest in design next to each other. They are not a head-to-head comparison. Each result is shown against the placebo group of its own trial, which is the only comparison each trial was built to make. Doses are the maintenance dose each arm was assigned, and weight results are the percentage change in body weight from the start of the trial.
An estimand is a trial's stated rule for what it is estimating, including how it counts people who stop treatment. Under the treatment-regimen estimand used for every weight figure below, people are analysed in the arm they were randomised to whether or not they kept taking the drug: TRIUMPH-1 equates it with intention-to-treat 17, and SURMOUNT-1 says it "assessed effects regardless of treatment discontinuation in the intention-to-treat population" 18.
Obesity without diabetes: each drug against its own placebo, not against the other
| Retatrutide: TRIUMPH-1 17 | Tirzepatide: SURMOUNT-1 18 | |
|---|---|---|
| Phase | 3 | 3 |
| Randomised | 2339 | 2539 |
| Population, as the abstract gives it | Adults with obesity without diabetes | Adults with a body-mass index (BMI) of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes |
| Mean baseline weight and BMI | Not given in the abstract | 104.8 kg; BMI 38.0 |
| Results reported at | 80 weeks | 72 weeks |
| Arms | 4 mg, 9 mg, 12 mg, placebo | 5 mg, 10 mg, 15 mg, placebo |
| Estimand | Treatment-regimen (intention-to-treat) | Treatment-regimen, intention-to-treat population |
| Weight change by arm | -17.6%, -23.7%, -25.0% | -15.0%, -19.5%, -20.9% |
| Weight change with its own placebo | -3.9% | -3.1% |
| Difference from its own placebo, as published | -19.8 percentage points (9 mg) and -21.0 (12 mg); none given for 4 mg | Not stated in the abstract |
| Published | New England Journal of Medicine, 29 September 2026 | New England Journal of Medicine, 2022 |
Obesity or overweight with type 2 diabetes: each drug against its own placebo, not against the other
HbA1c, glycated haemoglobin, is a blood measure of longer-term glucose control, and both trials set a range for it at entry.
| Retatrutide: TRIUMPH-2 19 | Tirzepatide: SURMOUNT-2 20 | |
|---|---|---|
| Randomised | 1152 | 938, all of whom received at least one dose |
| Population | Adults with type 2 diabetes, a BMI of 27 or higher and an HbA1c of 6.5 to 10.5% | Adults with type 2 diabetes, a BMI of 27 or higher and an HbA1c of 7 to 10% |
| Results reported at | 80 weeks | 72 weeks |
| Arms | 4 mg, 9 mg, 12 mg, placebo | 10 mg, 15 mg, placebo |
| Estimand | Treatment-regimen, with missing data imputed | Treatment-regimen |
| How the change is reported | Mean | Least-squares mean |
| Weight change by arm | -11.9%, -16.8%, -18.8% | -12.8%, -14.7% |
| Weight change with its own placebo | -5.1% | -3.2% |
| Difference from its own placebo | -6.9, -11.8 and -13.8 percentage points | -9.6 and -11.6 percentage points |
| Published | The Lancet, 29 September 2026 | The Lancet, 2023 |
Why the rows cannot be subtracted
Reading across a row and taking one figure from the other is the step these tables do not support. The trials differ in at least five ways.
- Different lengths. Both retatrutide trials reported results at 80 weeks 17 19, both tirzepatide trials at 72 18 20. TRIUMPH-1 also registers an extension subset followed to week 104, "Percent Change from Baseline in Body Weight in Participants in Extension Subset", which has not been published 21.
- No matched doses. The retatrutide arms were 4, 9 and 12 mg 17; the tirzepatide arms were 5, 10 and 15 mg 18. These are doses of two different molecules, so no arm is the counterpart of another.
- Different years. SURMOUNT-1 was published in 2022 18 and SURMOUNT-2 in 2023 20, both retatrutide trials on 29 September 2026 17 19.
- Populations described differently. SURMOUNT-1 states its BMI criteria and a mean baseline weight of 104.8 kg 18. The TRIUMPH-1 abstract states neither 17; its registry record gives similar entry criteria, a BMI of 30 or more, or 27 or more with a weight-related condition 21. Similar entry criteria do not make similar participants, and the published abstracts do not allow the two groups to be compared. In the diabetes trials the HbA1c entry ranges differ, 6.5 to 10.5% 19 against 7 to 10% 20.
- Placebo groups that moved by different amounts. Weight changed by -3.9% on placebo in TRIUMPH-1 17 and by -3.1% in SURMOUNT-1 18, and by -5.1% in TRIUMPH-2 19 against -3.2% in SURMOUNT-2 20.
That last point is the plainest. People given no active drug changed by different amounts in different trials, so part of any gap between two trials' figures can come from the trials themselves: who entered, for how long, and how they were followed. Only randomising people to both drugs within one trial removes that.
The network meta-analysis ranking, and what it rests on
A network meta-analysis ranks many drugs at once by comparing each with shared comparators, such as placebo, rather than in the same people. One published in BMJ Medicine in 2026 ranks retatrutide first for weight loss in adults with overweight or obesity without diabetes 22. Its data sources ran from 1 January 2000 to 6 March 2026, it required "a minimum intervention duration of 12 weeks", and it states: "Excluded were trials that enrolled participants with diabetes" 22. It reports that "58 trials of 24 214 participants were analysed" 22.
Compared with placebo, it reports that "weight loss was greatest with retatrutide (-22.10%, 95% confidence interval -25.60% to -18.60%), followed by tirzepatide (-19.28%, -20.39% to -18.16%)" 22. The authors qualify their own ranking: "confidence intervals overlapped for several comparisons", and they conclude that "limited head-to-head evidence, and residual uncertainty, however, should be considered" 22.
By the review's own dates and criteria, the only published retatrutide trial that appears eligible is the phase 2 obesity trial, which enrolled 338 adults and ran for 48 weeks 4. TRIUMPH-1 was published on 29 September 2026, after the search ended 17. TRIUMPH-2, TRANSCEND-T2D-1 and the phase 1b and phase 2 diabetes trials enrolled people with type 2 diabetes 19 3 23 24, and the phase 1 study gave single doses to healthy participants 25 26. So the retatrutide estimate rests, in effect, on one phase 2 trial whose weight results are least-squares means with no estimand named 4. That is this page's inference from the review's stated criteria; the review's abstract does not list the trials it included. The phase 2 trial's own results, with their context, are in the review of retatrutide's published trials.
The tirzepatide side is in a different position. Phase 3 tirzepatide trials in adults without diabetes were published well before the search ended; SURMOUNT-1, a 72-week trial of 2539 adults, appeared in 2022 18. Whether the review included it, its abstract does not say. So the ranking sets a single phase 2 trial of retatrutide, seen indirectly through shared comparators, against a tirzepatide estimate that phase 3 trials were available to inform.
The same review also reports that "Low certainty evidence suggested higher rates for discontinuing treatment with danuglipron and retatrutide" 22.
Safety, each on its own terms
The two safety records below are not ranked against each other. They come from different trials, in different people, over different periods, and the retatrutide record is the shorter one: no published retatrutide result covers more than 80 weeks of treatment 17 19, and its trial of cardiovascular and kidney outcomes has not reported 27.
Retatrutide
Gastrointestinal events were the most common adverse events in TRIUMPH-1, whose abstract gives no frequencies and no discontinuation rate 17. TRIUMPH-2 gives the most detail. Diarrhoea occurred in 27%, 34% and 34% of the 4 mg, 9 mg and 12 mg arms against 13% with placebo, and nausea in 14%, 21% and 28% against 8% 19. Hypotension, meaning low blood pressure, was reported in 1%, 5% and 6% against under 1%, and dysesthesia, an abnormal skin sensation, in 4%, 6% and 7% against 1% 19. Permanent discontinuation because of adverse events or death was 4%, 12% and 8% against 5%, a figure that is higher at 9 mg than at 12 mg 19. Two participants died in the 4 mg arm, three in the 9 mg arm, one in the 12 mg arm and one on placebo, and the investigator judged every death unrelated to the study intervention 19.
In TRANSCEND-T2D-1, a 40-week trial in type 2 diabetes, 2 to 5% stopped retatrutide because of adverse events against 0% on placebo, and no severe hypoglycaemia was reported 3. In the phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and declined thereafter; the abstract does not say by how many beats per minute 4.
Tirzepatide
In SURMOUNT-1, gastrointestinal events were the most common adverse events and most were mild to moderate, and adverse events led to stopping treatment in 4.3%, 7.1% and 6.2% of the 5 mg, 10 mg and 15 mg arms against 2.6% with placebo 18. In SURMOUNT-2, the abstract reports few adverse events leading to stopping treatment (under 5%), serious adverse events in 68 participants (7%) overall, and two deaths in the 10 mg arm that the investigator did not consider related to treatment 20.
In SURPASS-1, where tirzepatide was used on its own in type 2 diabetes, no clinically significant or severe hypoglycaemia was reported with tirzepatide 28. The US Zepbound label reports, as its own data from SURMOUNT-2, hypoglycaemia below 54 mg/dL in 4.2% of tirzepatide-treated patients against 1.3% on placebo 2. In SURMOUNT-OSA, there were two adjudicated confirmed cases of acute pancreatitis in the tirzepatide group of the trial whose participants used positive airway pressure 29. Pooling SURMOUNT-1 and SURMOUNT-2, the label reports adjudication-confirmed acute pancreatitis in 0.2% of tirzepatide-treated patients and 0.2% on placebo, and a mean rise in heart rate of 1 to 3 beats per minute against no increase with placebo 2.
Both US labels carry a boxed warning that tirzepatide causes thyroid C-cell tumours in rats and that it is unknown whether it causes them in humans, including medullary thyroid carcinoma, and both contraindicate it in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 2 30. The EU product information lists hypersensitivity as its only contraindication, and says of the rat finding: "The human relevance of these findings is unknown." 8
Retatrutide has no label, so it carries no boxed warning of any kind. That reflects its regulatory status, not a measured difference between the two drugs.
What each has been compared with directly
Tirzepatide has published head-to-head trials, all funded by Eli Lilly. SURMOUNT-5, an open-label phase 3b trial, randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or of semaglutide (1.7 mg or 2.4 mg) for 72 weeks, and the least-squares mean change in body weight at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide 32. Open-label means participants and investigators knew which drug each person received, and the trial had no placebo arm 32.
SURPASS-2, also open-label, randomised 1879 people with type 2 diabetes to tirzepatide 5 mg, 10 mg or 15 mg or to semaglutide 1 mg for 40 weeks, and HbA1c changed by -2.01, -2.24 and -2.30 percentage points with tirzepatide against -1.86 with semaglutide 33. Participants were taking metformin, according to the US Mounjaro label's description of the trial 30. Semaglutide 1 mg is a diabetes dose, not the one used for weight management, so this is not a weight comparison with semaglutide's obesity product.
SURPASS-CVOT, a double-blind trial, randomised 13,299 people with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide (up to 15 mg) or dulaglutide 1.5 mg, a drug its authors describe as already shown to reduce cardiovascular events 31. The combined endpoint of cardiovascular death, heart attack or stroke occurred in 801 people (12.2%) on tirzepatide and 862 (13.1%) on dulaglutide, a hazard ratio of 0.92 (95.3% confidence interval 0.83 to 1.01) 31. That met the trial's noninferiority test, meaning tirzepatide was shown to be no worse than dulaglutide within a prespecified margin (P = 0.003); the test of whether it reduced events more than dulaglutide did not reach significance (P = 0.09) 31.
No published retatrutide trial compares it with tirzepatide or semaglutide. Apart from a dulaglutide 1.5 mg arm in two published diabetes trials, a 12-week phase 1b trial and a phase 2 trial, no published trial has set it against another drug 23 24. TRANSCEND-T2D-2, an open-label phase 3 trial against semaglutide in adults with type 2 diabetes taking metformin with or without an SGLT2 inhibitor, has HbA1c at week 80 as its primary endpoint; its registry record gives an actual primary completion date of 27 August 2026 and no posted results 34. The trial against tirzepatide is TRIUMPH-5.
What will change the answer
TRIUMPH-5's registry record gives its official title as "A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity" 1. Its two arms are retatrutide, typed as experimental, and tirzepatide, typed as the active comparator, and its primary outcome is percent change from baseline in body weight at week 80 1. It is active and no longer recruiting, with an estimated enrolment of 800 and an estimated primary completion of November 2026, and it has posted no results 1. Its primary outcome is body weight in adults with obesity. It is not built around heart, kidney or liver events.
Both drugs also appear in SYNERGY-Outcomes, and it is not a head-to-head trial. It is a master protocol in adults with MASLD (metabolic dysfunction-associated steatotic liver disease, fat build-up in the liver linked to metabolic conditions) who are at increased risk of major adverse liver outcomes 35. Its arms are "Tirzepatide (TZ01)" and "Placebo (TZ01)", and separately "Retatrutide (RT01)" and "Placebo (RT01)", so each drug is compared with its own placebo 35. Its primary outcome is the time to a first major adverse liver outcome, over up to about 224 weeks, and it is recruiting, with an estimated 4,500 participants and an estimated primary completion of August 2030 35.
Then come the outcomes trials, each of one drug against placebo. For tirzepatide in adults with obesity, SURMOUNT-MMO, a trial of morbidity and mortality, is recorded as active and not recruiting, with an estimated primary completion of October 2027 36. For retatrutide, TRIUMPH-Outcomes has an estimated enrolment of 10,000 adults with a BMI of 27 or higher and atherosclerotic cardiovascular disease, chronic kidney disease or both, with time to a major adverse cardiovascular event and time to a kidney composite outcome as its primary endpoints, over up to about 248 weeks, and an estimated primary completion of February 2029 27.
Until TRIUMPH-5 reports, the comparison available is the one in the tables: two drugs from the same company, each measured against placebo in its own trials, in trials that differ in length, dose, year and the way their populations are described. Any figure that subtracts one drug's result from the other's is arithmetic done across trials, not a trial's finding.
Peptides covered
Research areas
Sources
- 1. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. 2026. NCT06662383(open access)
- 2. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 217806, S-041). U.S. Food and Drug Administration, Drugs@FDA. 2026. View source(open access)
- 3. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026. PubMed 42250575
- 4. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed 37366315
- 5. NDA 215866 approval letter, Mounjaro (tirzepatide) injection, May 13, 2022. U.S. Food and Drug Administration. 2022. View source(open access)
- 6. NDA 217806 approval letter, Zepbound (tirzepatide) injection, November 8, 2023. U.S. Food and Drug Administration. 2023. View source(open access)
- 7. NDA 217806 S-013 supplement approval letter, Zepbound (tirzepatide), obstructive sleep apnea indication, December 20, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
- 8. Mounjaro: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026. View source(open access)
- 9. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026. View source(open access)
- 10. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026. View source(open access)
- 11. Pre-approval Expanded Access of Retatrutide (LY3437943). ClinicalTrials.gov. 2026. NCT07629401(open access)
- 12. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound), December 19, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
- 13. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. 2026. View source(open access)
- 14. FDA Warning Letter, MARCS-CMS 721806, March 31, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 15. FDA Warning Letter, MARCS-CMS 734884, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 16. FDA Warning Letter, MARCS-CMS 696885, February 26, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
- 17. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. PubMed 42814954
- 18. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity.. The New England Journal of Medicine. 2022. PubMed 35658024
- 19. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026. PubMed 42810372
- 20. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. The Lancet. 2023. PubMed 37385275
- 21. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1). ClinicalTrials.gov. 2026. NCT05929066(open access)
- 22. Chen D et al. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials. BMJ Medicine. 2026. PubMed 42688617
- 23. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022. PubMed 36354040
- 24. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023. PubMed 37385280
- 25. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. PubMed 35985340
- 26. A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects. ClinicalTrials.gov. 2026. NCT03841630(open access)
- 27. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). ClinicalTrials.gov. 2026. NCT06383390(open access)
- 28. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. The Lancet. 2021. PubMed 34186022
- 29. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.. The New England Journal of Medicine. 2024. PubMed 38912654
- 30. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 215866, S-044 and S-045). U.S. Food and Drug Administration, Drugs@FDA. 2026. View source(open access)
- 31. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.. The New England Journal of Medicine. 2025. PubMed 41406444
- 32. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England Journal of Medicine. 2025. PubMed 40353578
- 33. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2021. PubMed 34170647
- 34. A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). ClinicalTrials.gov. 2026. NCT06260722(open access)
- 35. A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes). ClinicalTrials.gov. 2026. NCT07165028(open access)
- 36. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). ClinicalTrials.gov. 2026. NCT05556512(open access)